Anti-tumor activity of tumor necrosis factor alone and combination with VP-16 on renal cell carcinoma in a nude mice xenograft model.
- Author:
Soon Chul MYONG
1
;
Woo Chul MOON
;
Yong Sun KIM
Author Information
1. Department of Urology, College of Medicine, Chung-Ang University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
renal cell carcinoma;
tumor necrosis factor;
vp-16
- MeSH:
Animals;
Antineoplastic Agents;
Carcinoma, Renal Cell*;
Cell Line;
Etoposide*;
Heterografts*;
Humans;
Leukocytes;
Mice;
Mice, Nude*;
Necrosis;
Robenidine;
Tumor Necrosis Factor-alpha*
- From:Korean Journal of Urology
1992;33(6):954-960
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Investigations of the anti-tumor activity of recombinant mouse TNF and etoposide(VP-16) in a nude mouse subcutaneous implantation xenograft model utilizing the CURC-1 human renal cell carcinoma cell line were performed. Recombinant mouse tumor necrosis factor-alpha(rTNF-alpha) and VP-16. both well known cytotoxic and cytostatic anticancer agents were evaluated singly and in combination against subcutaneously growing CURC-1. The results were as follows : 1. In the absence of treatment(Group I). subcutaneously growing CURC-1 tumor nodules demonstrated continued rapid growth. 2. Administration of rTNF(Group II) induced significant tumor regression in the subcutaneous nodules. 3. Administration of rTNF and Etoposide(Group III) demonstrated significant tumor growth inhibition. On histopathological findings, Group I (control) shows rare leukocyte infiltration and no tumor necrosis. In contrast, Group II shows tumor necrosis and more leukocyte infiltration than Group I . Group III demonstrates tumor necrosis. tumor cell degeneration and more leukocyte infiltration than Group II. These results suggest that TNF have antineoplastic effect against subcutaneous human renal cell carcinoma nodule but the synergistic effect of TNF with VP-l6 is uncertain.
